Conference: 2010 International PHA Conference and Scientific Sessions
Release Date: 06.22.2010
Presentation Type: Scientific Sessions
With newly available therapies the prognosis of pulmonary hypertension (PH) is improving, with an approximately 85% survival rate at 1 year. But the problems of diagnosing, treating, and ultimately curing PH certainly remain. Limitations in current therapeutic options necessitate that both basic and clinical research in lung vascular diseases remain a high priority for The National Heart, Lung, and Blood Institute (NHLBI). The NHLBI supports a vigorous program of basic and translational research in PH. The NHLBI funded $33.3 million in FY 2008 and $41.4 million in FY2009 in PH research. Projects supported by NHLBI range from studies of the molecular basis for lung vascular lesion development in PH, to epidemiologic investigations of right ventricular function in health and disease. In addition, the American Recovery and Reinvestment Act of 2009 (ARRA) provided unique additional support for novel PH projects. Examples of ARRA-supported research include projects looking for new delivery methods of known efficacious PH drugs, novel therapeutic approaches using cell-based therapy, and screening for biomarkers of disease in pediatric PH.
The purpose of this talk will be to highlight the NHLBI portfolio of ongoing PH research, including the ARRA-supported efforts. This talk will also present a summary of recommendations from experts in lung vascular medicine and research that emerged from an NHLBI-Office of Rare Diseases Research (ORDR) Workshop held in 2010. New grant mechanisms designed to help catalyze translational research in lung diseases will also be introduced. At the end of the presentation, the conference participants should have gained an appreciation of the current and emerging NHLBI support for PH research.